Applied DNA Sciences to Present 'The Power of DNA in Detecting and Defeating Pharmaceutical Counterfeiting' at the Anti-Counterf
January 29 2007 - 6:30AM
PR Newswire (US)
STONY BROOK, N.Y., Jan. 29 /PRNewswire-FirstCall/ -- Applied DNA
Sciences, Inc. (OTC:APDN) (BULLETIN BOARD: APDN) , a DNA security
solutions company, today announced that Dr. James A. Hayward, Chief
Executive Officer, will deliver a presentation at the
Anti-Counterfeiting for Pharmaceuticals Conference to be held
January 30-31 in Philadelphia, PA. The counterfeiting of
pharmaceuticals is a large and growing problem throughout the
world. It has been estimated that the pharmaceutical industry loses
$32 billion to counterfeiting globally each year (U.S. Chamber of
Commerce). A study by Columbia University's National Center on
Addiction and Substance Abuse documented that only 11% of internet
pharmacies are legitimate. In 2006, the Center for Medicine in the
Public Interest predicted that counterfeit drug sales would
increase more than 90% from 2005 levels to reach $75 billion
globally by 2010, nearly twice the growth rate of legitimate
pharmaceuticals. According to the World Health Organization, over
10% of the global medicine market is estimated to be counterfeit,
posing a health threat to patients everywhere. Dr. Hayward's talk,
entitled "The Power of DNA in Detecting and Defeating
Pharmaceutical Counterfeiting," will address this disturbing trend
and present the use of DNA embedment to combat counterfeiting in
pharmaceuticals. DNA embedment offers a broadly applicable,
convenient and inexpensive way to help protect pharmaceuticals from
counterfeiting. APDN's platform for DNA embedment, uses unique DNA
"chimers," is derived from botanical sources, and is marketed as
the "SigNature" brand. The SigNature DNA Markers are highly
resistant to reverse engineering or replication, and can either be
applied independently or to supplement other security taggants in
order to allow for a forensic level of authentication. APDN's
SigNature DNA Markers can easily be embedded directly into
pharmaceutical packaging, combined with RFID (radio frequency
identification) tags, holograms, or EPC's (electronic product
codes). APDN has demonstrated that our SigNature DNA markers may be
applied directly onto single unit doses of drugs such as pressed
tablets, and thereby ensure drug authenticity regardless of
packaging. "This is a rapidly growing problem which threatens the
health and safety of people everywhere." Dr. Hayward stated.
"APDN's SigNature Program can quickly and reliably authenticate and
identify counterfeit versions of pharmaceuticals, diminishing
product diversion and enabling companies to detect, deter,
interdict and prosecute counterfeiting enterprises and individuals.
I welcome this opportunity to introduce the potential power of our
DNA technology as both a way to deter counterfeiting and help
protect patients." About Applied DNA Sciences, Inc. Applied DNA
Sciences, Inc. (APDN) provides botanical DNA encryption, embedment
and authentication solutions that can help protect companies,
governments and consumers from counterfeiting, fraud, piracy,
product diversion, identity theft and unauthorized intrusion into
physical locations and databases. Our common stock is registered
under Section 12(g) of the Securities Exchange Act of 1934 and is
listed on the Over-The-Counter Bulletin Board under the symbol
"APDN". Contact: Debbie Bailey, Applied DNA Sciences, Inc., 25
Health Sciences Drive, Stony Brook, New York 11790; Tel: 631-444-
8090; Fax: 631-444-8848 http://www.adnas.com/. The statements made
by Applied DNA Sciences, Inc. may be forward-looking in nature and
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements describe the Company's future plans, projections,
strategies and expectations, and are based on assumptions and
involve a number of risks and uncertainties, many of which are
beyond the control of Applied DNA Sciences, Inc. Actual results
could differ materially from those projected due to our short
operating history, limited market acceptance, market competition
and various other factors detailed from time to time in Applied DNA
Sciences' SEC reports and filings, including our Registration
Statement on Form SB-2 as amended, and our Annual Report on Form
10-KSB, filed on January 16, 2007. The Company undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
hereof to reflect the occurrence of unanticipated events.
DATASOURCE: Applied DNA Sciences, Inc. CONTACT: Debbie Bailey,
+1-631-444-8090, fax: +1-631-444-8848, of Applied DNA Sciences,
Inc. Web site: http://www.adnas.com/
Copyright